ClinicalTrials.gg
CompletedNCT04914923MindOCUpdated Nov 20, 2026

Mindfulness-Based Interventions for OCD

An interventional study of Muse and Cognitive Behaviour Therapy (CBT) in Obsessive-Compulsive Disorder, sponsored by Sunnybrook Health Sciences Centre. Completed at 2 sites in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Obsessive-Compulsive Disorder by Sunnybrook Health Sciences Centre — 3 open to participants now, 5 under way, none of them phase 3. Obsessive-Compulsive Disorder · Sunnybrook Health Sciences Centre.

Enrollment
Largest of 12
297 · median 17
Started
2021
with 1 other
No phase
10 of 13
1 open now
Registered
9th of 13
by date

Among the 13 studies in Obsessive-Compulsive Disorder by Sunnybrook Health Sciences Centre, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 10 with no phase, and was the 9th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

3 of the 13 studies in Obsessive-Compulsive Disorder by Sunnybrook Health Sciences Centre are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Obsessive-Compulsive Disorder by Sunnybrook Health Sciences Centre, or all of them as a file.
02

Study summary

Obsessive-compulsive disorder (OCD) is a severe and debilitating anxiety disorder afflicting about 2% of the population. It is characterized by the presence of recurrent obsessions and/or compulsions that are time consuming and cause marked distress and/or impairment. Untreated, OCD runs a chronic and deteriorating course. According to the World Health Organization, OCD is among the top 10 leading causes of disability worldwide. Examination of non-medicinal treatments for OCD has focused on two distinct treatments: exposure and response prevention (ERP) and cognitive therapy (CT), often combined into an integrated cognitive-behavioural treatment (CBT). CBT is considered the first line psychological treatment for OCD, with estimates of response rates of between 70-80%. However, there are a significant number of treatment non-responders and the majority of responders are still left with impairing residual symptoms. One area of investigation that has shown potential benefit for general mood and anxiety disorders has been mindfulness-based interventions (MBIs), yet the potential benefits of MBIs in OCD has been largely unexamined, except for several small preliminary studies that show clinical promise. The purpose of this study is to examine the clinical benefits of a standardized MBI treatment for OCD in a large-scale, multi-site randomized controlled trial. The results of this study will directly determine whether Mindfulness can be considered an effective treatment for OCD. If this study can demonstrate that a short-term mindfulness intervention can significantly reduce the suffering associated with OCD, then the findings could easily be translated into routine clinical care in and out of hospital settings. Results of this study will also potentially add to our understanding of the mechanisms that drive OCD symptoms, improve our knowledge of psychological treatment mechanisms, and elucidate how biological factors influence psychological treatment outcomes.

Read the detailed description

Cognitive Behavioural Therapy (CBT) is a first line psychological treatment for OCD with estimated response rates of between 70-80%. However, there are still a substantial number of treatment non-responders and the vast majority of responders are left with impairing residual symptoms. One new area of investigation that has shown potential benefit for the treatment of OCD has been mindfulness-based interventions (MBIs). This emerging literature provides proof of principle for the delivery and potential efficacy of MBIs for OCD, particularly as an adjunct to CBT, with all studies reporting large (d > .80) treatment effects. To date, only our teams' small, non-controlled pilot study (N=19) has shown promise for a MBI as a stand-alone treatment for OCD separate from CBT (d = 1.10). However, all results to date for MBI treatments for OCD must be interpreted with caution as they have utilized small, underpowered sample sizes, have not included control groups, and failed to control for potentially confounding variables (e.g., medications, self-initiated exposures). The proposed four-year, two-site randomized controlled trial at two of Canada's leading OCD treatment centres (Sunnybrook Health Sciences Centre and St. Joseph's Healthcare Hamilton) that have been involved in developing and piloting MBI treatments for OCD will aim to test whether a structured, Mindfulness-Based Cognitive Therapy (MBCT) intervention for OCD is an efficacious treatment for a large, heterogeneous sample of DSM-5 (Diagnostic Statistical Manual of Mental Disorders 5th edition) diagnosed OCD participants. The primary aim of this proposed study is to examine whether a developed and piloted MBCT treatment for OCD is efficacious when compared to a waitlist condition and to explore its efficacy compared to CBT treatment for OCD. A secondary aim of the study is to examine the putative treatment mechanisms of MBCT. Past research examining treatment mechanisms in CBT for OCD have focused on the reduction of obsessional beliefs, anxiety sensitivity, and safety behaviours in producing better outcomes. In contrast, the hypothesized mechanisms in MBI treatments include the development of mindfulness skills such as acting with awareness, non-reactivity to and non-judging of inner experience, and reduction in mind wandering. The large-scale, powered RCT (randomized control trial) design will permit the examination of whether MBCT and CBT include overlapping or distinct treatment mechanisms. Treatment outcomes will be assessed with standardized measures of OCD symptomatology, general measures of mood and anxiety, a reliable and valid EEG measure to assess cognitive changes across treatment. If this study can demonstrate that a short-term mindfulness intervention can significantly reduce the suffering associated with OCD, then the findings could easily be translated into routine clinical care in and out of Canadian hospital settings. Results of this study will also potentially add to our understanding of the mechanisms that drive OCD symptoms, improve our knowledge of psychological treatment mechanisms, and elucidate how genetic/biological factors influence psychological treatment outcomes.

03

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • Cognitive Behaviour Therapy
  • Mindfulness-based Intervention
  • Mindfulness-based cognitive therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • experiencing obsessive-compulsive symptoms based on the Yale-Brown Obsessive Compulsive Scale (YBOCS; score > 17)
  • if on medications for OCD, must be stabilized, i.e. are currently receiving an adequate dose (equivalent of 40mg/day of fluoxetine) for an adequate duration (at least 8 weeks of treatment) prior to the initiation of the study.

Exclusion criteria

Exclusion Criteria:

  • concurrent diagnosis of a severe mood disorder, schizophrenia or other psychotic disorders, or substance abuse/dependence
  • suspected organic pathology
  • an active comorbid medical condition that may require urgent intervention during the treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
297 participants (actual)

Study arms

  • Experimental
    Cognitive Behaviour Therapy

    This study arm will receive 12 weeks of cognitive behaviour therapy as an intervention.

    Behavioral: Cognitive Behaviour Therapy (CBT)

  • Experimental
    Mindfulness-based Cognitive Therapy

    This study arm will receive 12 weeks of a mindfulness-based cognitive therapy intervention, along with open mindfulness sessions via an EEG headset.

    Device: Muse · Behavioral: Mindfulness-Based Cognitive Therapy (MBCT)

  • No intervention
    Waitlist

    This study arm will not receive an intervention for 12 weeks.

Interventions

  • DeviceMuse

    Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.

  • BehavioralCognitive Behaviour Therapy (CBT)

    Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.

  • BehavioralMindfulness-Based Cognitive Therapy (MBCT)

    Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.

06

What researchers measure

Primary outcomes

  1. Change from baseline in OCD symptom severity, as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

    OCD symptom severity will be measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS).The YBOCS is a standardized rating scale measuring 10 items pertaining to obsessions and compulsions on a 5-point Likert scale ranging from 0 (no symptoms) to 4 (severe symptoms). Both the self-report and clinician interview versions of the YBOCS have been shown to possess high internal consistency and validity.

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. Change from baseline in OCD symptomatology, as measured by the OCI-R (Obsessive Compulsive Inventory - Revised).

    This self -report short version of the OCI consisting of 18 items measures six distinct factors: Washing, Checking, Ordering, Obsessing, Hoarding and Neutralizing, to chart the change in OCD symptomatology across time.

    Time frame: Baseline to 12 weeks

  2. Change from baseline in the experience of depression, anxiety and stress symptoms, as measured by the DASS-21 (Depression, Anxiety and Stress Scale - 21 items).

    Depression, anxiety and stress severity will be measured using the Depression Anxiety Stress Scales-21,a self-report questionnaire comprising three subscales with seven items each for depression, anxiety and stress. The DASS-21 shows high internal consistency, high reliability in distinguishing between depression, anxiety and stress in adults, and good convergent and discriminant validity.

    Time frame: Baseline to 12 weeks

  3. Change from baseline in various attitudes and beliefs related to obsessional thoughts, as measured by the OBQ-44 (Obsessional Beliefs Questionnaire - 44 items).

    The Obsessional Beliefs Questionnaire is a 44-item self-report questionnaire designed to assess the extent to which respondents agree or disagree with various attitudes and beliefs related to obsessional thoughts. The OBQ is internally consistent, and evidences good test-retest reliability, convergent validity, and discriminant validity.

    Time frame: Baseline to 12 weeks

  4. Change from baseline in aspects of mindfulness, as measured by the FFMQ (Five Facet Mindfulness Questionnaire).

    The Five Facet Mindfulness Questionnaire is a self-report questionnaire containing 39 items that assess five aspects of mindfulness: observing, describing, acting with awareness, non-judgment of inner experiences, and non-reactivity to inner experience.

    Time frame: Baseline to 12 weeks

  5. Change from baseline in functional health and well-being, as measured by the SF-36 Health Survey (Short Form 36 item Health Survey).

    The SF-36 Health Survey is a brief questionnaire containing 36 items about functional health and well-being. The reliability and validity of the SF-36 have been well documented. It has demonstrated good treatment sensitivity

    Time frame: Baseline to 12 weeks

  6. Change from baseline in the degree which individuals find distress intolerable, as measured by the DTS (Distress Tolerance Scale).

    The Distress Tolerance Scale is a 15-item self-report questionnaire that measures the degree to which individuals find distress intolerable, unacceptable, impairing, and necessary to avoid. Distress tolerance has been linked to OCD.

    Time frame: Baseline to 12 weeks

  7. Change from baseline in the fear of consequences of anxiety, as measured by the ASI-3 (Anxiety Sensitivity Index).

    The Anxiety Sensitivity Index-3 is an 18-item self-report measure of the degree to which individuals fear the consequences of anxiety. It is composed of three subscales: fear of the physical, social, and cognitive consequences of anxiety.

    Time frame: Baseline to 12 weeks

  8. Change from baseline in the time spent ruminating, as measured by the RRS (Ruminative Response Scale).

    The Ruminative Response Scale is a frequently used 22-item measure of the amount to which participants are engaging in rumination, or repetitive, passive, and negative self-focus.

    Time frame: Baseline to 12 weeks

Other outcomes

  1. Change from baseline in OCD symptomatology, as measured by the EEG headset device "Muse".

    Participants will be instructed to use the "Muse" EEG headset for open, unguided mindfulness sessions. The device will measure alpha and beta band oscillatory power and how it will change over the 12 weeks of treatment intervention.

    Time frame: Baseline to 12 weeks

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Mar 2026, 52 months.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's 52 months is above that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2021
First posted
Jun 7, 2021
StartActual
Nov 9, 2021
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 20, 2026
Enrollment
420 (estimated)→297 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Active, not recruiting→Completed
    Enrollment 420 (estimated)→297 (actual)
    + 3 other changes: verification date, date precision and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04914923
Responsible party
Sponsor
First posted
Jun 7, 2021
Start date
Nov 9, 2021
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Nov 20, 2026

Study contacts

Neil A Rector, PhD
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion